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Abstract 
 
The status of carrageenan in the regulatory sphere influences how and where it may 
be used, with implications for seaweed farmers, carrageenan manufacturers and 
consumers. Over the period 1935 to the present the status of carrageenan has been 
effected by changes in the regulatory environment that reflect new understandings 
about carrageenan, health and health risks as well as broader trade, social and political 
changes. This paper reviews regulatory progress from the 1930s to the present.  It 
reflects, in particular, the shifting priorities in public health and their effects on the 
regulatory status of carrageenan.  Four case studies of public controversies about 
carrageenan safety are discussed in relation to regulatory responses and their public 
health significance.  It is concluded that current assessments of risk associated with 
carrageenan have, in some contexts, failed to take into account the full spectrum of 
safety assessments that have been carried out and the maturing of food additive 
regulations thereby allowing a myth of risk to continue. 
 
Key words: carrageenan, degraded carrageenan, health risk, poligeenan, public health, 
food regulation 
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Introduction 
 
Carrageenan is approved and widely used as a food additive (Bixler, 1996; Shah et al., 
2003). Despite official sanction for use in food, over the last 50 years, carrageenan 
has been subjected to intense scrutiny for potential health risks associated with human 
consumption. Controversy and debate about carrageenan and human health have 
periodically flared in academic literature and the media (see for example Borthakur et 
al., 2007; Chapman, 2001; Cohen et al., 2002; Marcus et al., 1969; Shah et al., 2003; 
Tobacman, 1998, 2001; Tobacman et al., 2001a; Tomarelli et al., 1974).  
 
Regulatory authorities, and independent scientific advisory committees, have 
maintained the position that carrageenan is safe for human consumption. Carrageenan 
is approved for use by the Food and Drug Administration (FDA) in the United States 
(Food and Drug Administration, 2006)  by the European Parliament and Council 
(Commission Directive, 1995), and by the Joint World Health Organization and by 
the Food and Agriculture Organization Expert Committee on Food Additives (Cohen 
et al., 2002). Yet in some jurisdictions precautionary measures have been instigated 
that place restrictions on where and how carrageenan may be used: Carrageenan is not 
permitted for use in infant formula in Europe (European Parliament and Council, 
1995) but is permitted for use in the US (Food and Drug Administration, 2004).  
 
The Scientific Committee on Food (SCF) of the European Commission recently 
endorsed a molecular weight distribution limit on carrageenan that is more restrictive 
than is the case in the US (Scientific Committee on Food, 2003a). At the same time, 
the SCF acknowledges „„there is no evidence … that exposure to low molecular 
weight carrageenan from the use of food-grade carrageenan is occurring.‟‟  This 
precautionary approach provides a rationale for adverse public and government 
response in Europe that is not necessarily matched elsewhere. This example illustrates 
the regulation of carrageenan is not uniform internationally; and controversy on the 
use of carrageenan has not been resolved to the satisfaction of all (Borthakur et al., 
2007). 
 
Legislative action in relation to food safety issues is progressive (Merrill, 1997). This 
paper reviews the history of carrageenan from the time that it began to be industrially 
manufactured for food use in the US to the present.  While differences still exist, there 
has been a growing move in recent years towards international harmonisation of food 
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regulation through the Codex Alimentarius system and the EU Commission (Garrett 
et al., 1998; Livermore, 2006; Millstone et al., 2002; Veggeland et al., 2005).  
 
Four examples are discussed in which carrageenan use in foods has been associated 
with risks to human health:  carcinogenicity and ulceration in the 1960s; baby formula 
concerns in the 1980s, more recently controversy surrounding the publications of Dr. 
Joanne K. Tobacman and the appearance of weak mutagen in carrageenan. 
Carrageenan as a regulated food additive in the US 
 
Until the late 1930s, what is now recognised as carrageenan (extract) was not widely 
used as a substance added to food and the term carrageenan did not exist in 
regulations for foods.  Decoctions of the seaweed Chondrus crispus had a long history 
of safe use in herbal and pharmaceutical preparations (See for example Council of the 
Pharmaceutical Society of Great Britain, 1911; Felter et al., 1898).  Decoctions were 
made by macerating the seaweed with water or milk. The gelling properties of 
Chondrus crispus had also been utilised for centuries in food products, such as the 
dessert blancmange (Stanley, 1987). In 1862 Stanford coined the term “carrageenin” 
for the extract of Chondrus crispus; the spelling was later changed to carrageenan by 
the American Chemical Society to reflect the use of –an as an affix denoting the 
presence of a polysaccharide (McHugh, 2003). 
 
Despite knowledge of the properties of carrageenan-bearing seaweed in the mid 
nineteenth century, it was almost a further century before a commercial industry 
based on the extracting carrageenan from certain seaweeds developed. In the US in 
1937 ground Chondrus crispus was found to stabilise dairy-produced chocolate milk. 
Three years later the Chicago based dairy company, Krim-ko, established a small 
plant near Boston to manufacture a water extract of Chondrus for chocolate milk and 
junket (Chapman, 1950; Lewis et al., 1988). Algin Corp of America in Rockland, 
Maine (later to become Marine Colloids, Inc and later still FMC Biopolymer) 
commercialized carrageenan extraction in the US in the 1950s.  About the same time 
production of carrageenan began in Denmark and France. 
 
Chondrus crispus (carrageenin) was regulated in food regulations in the US first as a 
GRAS substance, defined as a substance generally recognised as safe following the 
1958 Miller amendment to the US Food and Drug Act of 1938 (See Table 1 for a 
chronology of regulation of carrageenan). Under the Miller amendment the FDA 
divided substances added to food into regulated food additives and substances that 
were GRAS either due to their history of use in food prior to the 1st January 1958 (the 
so-called grandfather clause) or on the basis of a consensus of expert opinion. The 
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Miller amendment prohibited the use of any new food additives considered 
inadequately tested for safety.  
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Table 1 Summary of US Regulation of Carrageenan 
 
Year Event Status of carrageenan Stated aims 
1906 Federal Pure Food and 
Drugs Act and Federal 
Meat Inspection Act 
Extract not yet developed. 
Carrageenan-bearing 
seaweeds little valued as 
food in US however long 
history of use in Ireland 
and elsewhere. 
Regulates safety and 
quality of food. Defines 
official recipes for some 
products/prohibits food 
„adulteration‟. 
1938 Federal Food, Drug and 
Cosmetics Act 
1937, Krim-ko company, 
Chicago  used ground 
Chondrus as ingredient 
for chocolate milk 
suspension. Not 
regulated. 
Replaces Pure Food Act. 
Among provisions, 
labelling requirements 
were increased to include 
some „truthful‟ listing of 
ingredients and additives 
on some products. Full 
ingredient listing not 
required on „standardised 
products‟. 
1958 Food Additives 
Amendment  
Also 
Delaney clause 
21CFR182.7255  
Carrageenin (Chondrus 
extract) classified 
„Generally Recognised as 
Safe‟ due to long history 
of use in foods. 
Provides for a pre-market 
approval system for 
ingredients „added to 
food‟. Delaney clause 
gives FDA powers to ban 
food additives found to 
induce cancer in „people 
or animals‟. Classifies 
over 10,000 substances as 
food additives. 
1960   MCInc. petition FDA to 
expand GRAS list. 
Carrageenan listed as a 
food additive under 
21CFR172.620  
Expanded list of 
carrageenan-bearing 
seaweeds. Carrageenan 
defined according to 
species list of eight 
seaweeds. 
1969 White House Conference 
on Food, Nutrition and 
Health 
1972 FDA review: 
molecular weight 
limitations proposed 
Recommends a review of 
GRAS substances 
following FDA‟s ban of 
the artificial sweetener 
cyclamate as a potential 
carcinogen under the 
Delaney clause.  
1973 FDA regulations for 
nutritional labelling of 
food introduced 
1979 FDA move away 
from issuing molecular 
weight requirement and 
through Food Chemical 
Codex adopted water 
Voluntary for most foods, 
required for foods with 
added nutrients. 
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viscosity test to mimic 
molecular weight. 
1990 Nutrition Labeling and 
Education Act 
Carrageenan used for fat-
replacement in meat 
(under auspices of 
USDA) 
Requires mandatory 
labelling of nutrition of 
all processed foods, plus 
increased „clarity‟ of 
ingredients labelling. 
 
 
Chondrus extract was grandfathered by the 1958 Amendment to the GRAS status 
through its previous uses. Under the GRAS listing Chondrus extract (carrageenin) was 
permitted for use in food under section 21CFR182.7255 of the US Code of Federal 
Regulations as harmless under prescribed conditions of use. However, for Marine 
Colloids Inc., the status of Chondrus extract limited production capability. The 
wording of the GRAS legislation allowed just one seaweed species from which 
carrageenan could be derived: Chondrus crispus.  
 
During the early part of the 1950s a rapid increase in demand, and limited supply of 
Chondrus crispus, led industry to explore other seaweed species as a source of the 
extract that was recognised by its chemical name carrageenan (Chopin, 1998). From 
the 1950s into the 1960s the industry was experiencing other changes: increased 
knowledge of carrageenan chemistry and improved processes for optimizing 
carrageenan performance in foods.  Industry members became interested in how to 
develop the raw materials supply through the use of a broader range of seaweed 
species, and through increasing interest in cultivation.  In 1960 Marine Colloids Inc. 
petitioned the FDA to alter the GRAS listing and to permit carrageenan to be defined 
by its chemistry, rather than the seaweed source.  FDA did not accept the chemistry 
definition but agreed to expand the seaweeds from which carrageenan could be 
extracted.  To effect this change the FDA moved to list carrageenan as a regulated 
food additive under section 21CFR172.620, with the expanded, but limited, list of 
seaweed species and to establish a few purity criteria.  Some confusion was created 
when Chondrus extract (carrageenin) was still listed as GRAS, and the extract of 
Chondrus crispus - „carrageenan‟ was listed as a regulated food-additive, a situation 
that still exists.   
 
The 1938 Act (See Table 1) was essentially a „policing statute‟ to ensure government 
had the authority to address dangers associated with foods or constituents of food that 
were considered „injurious to health‟(Merrill, 1997). The origins of the Act can be 
traced to concerns about food adulteration in the late 19th and early 20th centuries 
(Coveney, 2003). Following World War II significant advances in processing, 
preservation and packaging were developed that  led to an increased interest and use 
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of food processing aids (Atkins et al., 2000). The 1938 Act did not require advance 
approval for substances added to foods and processing aids could be widely adopted.  
In 1952 the US Congress established a special commission, chaired by Congressman 
James Delaney, to consider the growing use of chemical processing aids in foods and 
the implications for consumer health. The resultant Food Additives Amendment 
(1958) was based on an assumption that anything added to food was adulterated 
unless it met with prior approval of the FDA, or unless there was already a long 
history of safe use (Merrill, 1997). Proving safety of new additives became the 
responsibility of manufacturers (Food and Drug Administration, 2004).  The treatment 
of carrageenan was far from unique.  Other GRAS substances came under specific 
regulations about this time (Food and Drug Administration, 1958; Merrill, 1997). 
 
The passage of food regulations transferred more and more responsibility from the 
Federal Government as enforcer of honesty and fairness, to focus on pre-market 
controls. Regulation of new substances added to food provided a scientifically 
verified guarantee of safety that was not the case for GRAS category, however it also 
increased the surveillance of potential health risks by requiring manufacturers to 
prove, using scientific evidence, (usually from animal feeding studies) that any new 
additive was safe for human consumption.   
 
The development of food regulations in the US was a prelude to similar actions in 
Europe and in the FAO/WHO Codex Alimentarius; although occurring somewhat 
later and usually by-passing the GRAS concept. 
Four Case Studies of Public Health Controversy 
Case I:  The origin of concerns and regulatory action: Ebimar  
 
In the mid 1960s a UK company Glaxo (now GlaxoSmithKline Beecham) began to 
market a pharmaceutical product called Ebimar in France. It was based  on 
„carrageenin‟ which had been found to reduce the pain associated with peptic ulcers 
(Anderson et al., 1965; Bixler, 1996; Piper et al., 1961).  It was thought that stomach 
acids, including pepsin, contributed to the formation of ulcers (Anderson et al., 1965).  
Sulphated polysaccharides occurring naturally in the gastric mucous were found to 
inhibit the formation of pepsin. „Carrageenin‟ was proposed as a cheap and natural 
alternative to other synthetic sulphates of polysaccharides that had been proposed as 
treatment agents.  
 
At the doses required, the carrageenan was extremely viscous and difficult to 
consume in quantities thought necessary to produce a positive health benefit.  It is 
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well known that the viscosity of these solutions [carrageenin] could be reduced or 
destroyed by controlled heating with dilute mineral acid followed by purification.  
C16, the polygalactose sulfate component of Ebimar, was the product of this 
technology. 
 
Given the limited knowledge of peptic ulcer causation, there was a correspondingly 
weak understanding of how or why the product worked. In the late 1960s, Marcus and 
Watt, two researchers under contract to the developers of Ebimar, undertook research 
to establish the mechanism through which low molecular weight carrageenan worked. 
During animal experimentation with both hydrolysed (C16) and unhydrolysed 
carrageenan, the latter being the type used in foods, Marcus and Watt (1969) 
discovered that, at very high doses, both could produce ulcerations in the cecum of the 
guinea pig, but ulcerations were more severe with the degraded form.  Furthermore, 
the dose below which food-type carrageenan caused no further ulcers still showed 
considerable ulceration with C16.  Marcus and Watts went on to speculate this 
ulceration as a precursor to the disease ulcerative colitis. 
 
This is a good point to introduce some nomenclature that is common knowledge today 
among scientists and regulators, but was a source of confusion in the 1960s and 
continues to be one for the general public.  C16 today would be called “poligeenan” a 
name provided by the US Adopted Name Council (USAN).  While carrageenan is the 
raw material for producing poligeenan, the two different polymers have different 
properties and uses.  Poligeenan with an average molecular weight of about 20,000 
daltons has none of the food functions of carrageenan whose average molecular 
weight is never lower than 100,000 daltons and is usually much higher.  The only 
application today for poligeenan is as a component of an X-ray imaging diagnostic 
product.  Carrageenan for food use contains a very small fraction with a molecular 
weight in the range of that of poligeenan. Any suggestion that carrageenan with a 
small amount of low molecular weight matter could have the same ulcerating effect of 
poligeenan assumes equivalence between the substances. 
  
Watt and Marcus concluded that the “…significance of our results in relation to 
human ulcerative colitis is at present only speculative and must await more 
comprehensive investigation” (Marcus et al., 1969, p. 188S). In 1969, carrageenan use 
in food was already widespread and as Marcus and Watt reported, at the time of their 
publication there had been „no reports of adverse effects‟ associated with carrageenan 
usage (Marcus et al., 1969, p. 187S).  
 
One effect of the Marcus and Watt publication was further surveillance and concern 
about carrageenan safety.  Under FDA guidelines it was the responsibility of industry 
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to prove carrageenan safe. Industry members conducted further studies involving 
other animal species. In 1972, the FDA reviewed carrageenan safety in light of 
Marcus and Watt‟s research and all the studies that had been generated as a result of 
their findings (Informatics Inc., 1972) 
 
On the basis of the Informatics report, the FDA arranged a meeting with health 
professionals and industry representatives to discuss a motion to modify the 
regulations for carrageenan in light of concerns about ulcerations found in the Watt 
and Marcus studies. It was agreed that the issue was of little significance to human 
health. Nevertheless, precautionary measures were proposed to limit the molecular 
weight to a minimum of 100,000 and to seek further animal studies to confirm this 
decision.  Since 1969 scientific assessments of carrageenan have included short-term 
and long-term generational studies involving different dosages of degraded and non-
degraded forms, and various animal studies including rats, mice, rabbits, rhesus 
monkeys, squirrel monkeys, pigs, gerbils, baboons, hamsters, ferrets, chick embryos 
and dogs (Cohen et al., 2002; Greig, 1999; JECFA, 1974, 2001), While much of the 
above work was going on in the United States, various of the toxicology studies were 
also carried out in Europe.   
 
All of the studies supported the safety of carrageenan for use in foods.  Regulatory 
authorities saw no reason to question the safety of carrageenan as long as the average 
molecular weight was 100,000 daltons or higher. 
 
Regulations were modified to insure that carrageenan used in foods would meet this 
limit, and a simple water viscosity measurement was adopted for this purpose. 
As a further precautionary measure, Europeans limited the „Acceptable Daily Intake‟ 
of 75mg/kg body weight/day, an amount well above any average daily intake of even 
a diet high in carrageenan content (Bixler, 1994).  More recently JECFA increased the 
ADI to “not specified” meaning the use of carrageenan in foods allowed was for 
technical functionality reasons and the amount used did not have to be numerically 
specified (JECFA, 2001).    
 
While the above work should have settled the carrageenan safety for food processors, 
it did not.  In 1984 labelling of food additives using the E number system came into 
effect among members of the European Economic Community. In the UK, additives 
had not previously been listed on food products.  E numbers on food labels revealed 
additives to supermarket shoppers for the first time.  The E numbers were widely 
interpreted by the public as new chemicals being added to food, rather than as existing 
additives being declared (London Food Commission, 1988, p. 39). In May 1986 
eighty-nine MPs from across all parties signed a motion to seek a ban on all 
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unnecessary additives in children‟s food. In January 1987 the Ministry of Agriculture, 
Fisheries and Food (MAFF) in the UK made public a survey of public attitudes to 
food additives. The survey revealed that one third of the British public could not see 
any justification for using additives at all (MAFF, 1987). The survey was significant 
in demonstrating the failures of policy communication about food additives, but also 
was linked to a more general decline of public trust in food policy and regulation 
(Lang, 1999). With increasing public concern about additives, and a declining trust in 
public institutions, government regulators in the UK were under intense public 
scrutiny. Consumer groups were particularly active in voicing concern about baby 
foods and pre-schoolers diets (Bixler, 1996). 
Case II Infant formula and carrageenan  
 
As already noted above, no foodstuff attracts more attention about safety than infant 
formula used in the first 4-6 months of a human life. It is considered particularly 
important because it may be the sole source of nutrition for infants over an important 
period of their physical development. Infant formula became a key policy concern 
early in the twentieth century along with population-based measures indicating 
declining rates of breastfeeding in industrialised countries, and increased scientific 
understanding of the importance of nutrition (Murphy, 2004; Wolf, 2003). 
Carrageenan had been used in the US since the late1950s in liquid infant formulas to 
prevent fat separation and thereby assure more uniform nutrition.  However, Marcus 
and Watt‟s research generated sufficient concern to warrant further investigation.   
 
In the FDA‟s1972 review of carrageenan, the use of carrageenan in liquid infant 
formula was considered, and it was decided the benefits of using carrageenan noted 
above outweighed any risk to the infant.  Even though the terms of the 1958 Food 
Additive Amendment did not permit any public health benefits to be taken into 
account in determining the safe use of additives, practical considerations made it hard 
for regulatory authorities to exclude benefits in a risk assessment. 
 
In Europe carrageenan is not permitted as a food additive for baby formula. The ban 
can also be traced to more general concerns about food additives that emerged in the 
1980s.  In 1992 the UK Food Advisory Committee in MAFF commissioned an 
extensive report on additives in baby milk and weaning formulas and concluded about 
carrageenan that: 
 
“Although there is no direct evidence of harm from carrageenan in infants and no 
toxicologically significant effects were seen in infant baboons fed carrageenan in 
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commercial infant formulae for 16 weeks, high levels of reassurance are needed to 
permit additives in infant formulae. The Committee could not exclude the possibility 
of absorption of carrageenan by the immature gut or the possibility that absorbed 
material might affect the immune system in the infant. The Committee does not 
therefore consider carrageenan acceptable for use in infant formulae (European 
Commission, 1992).” 
 
The decision to ban the use of carrageenan in infant formulae, because of the „high 
levels of assurance‟ needed, was subsequently reaffirmed by the EC-SCF (Scientific 
Committee on Food, 2003b). The SCF suggested that because there was insufficient 
information on the effect of carrageenan on the immature gut of babies, its use was 
inadvisable but they had „no objection to its use to the use of carrageenan, for 
technological reasons, in foods for older infants, such as follow-on formulae (SCF, 
1983) and weaning foods‟(Scientific Committee on Food, 2003b, p. 90). 
Industry has continued to support the benefits of using carrageenan in liquid 
infant formula and has sought to quantify risk and unequivocally assure safety 
to infants. New information has been provided to JECFA for their 2007 review of 
carrageenan.
13 
 
 
 
 
 
 
 
 
 
 
 
 
Case III The ‘Tobacman’ controversy 
 
Concerns about the use of carrageenan in food were not altogether assuaged despite 
the precautionary approaches adopted by various regulatory agencies and even though 
poligeenan, a suspected human carcinogen, is not and never has been used as a food 
additive. Poligeenan exists today specifically for diagnostic use only.  The small 
amount of low molecular weight material present naturally in carrageenan is 
considered of no safety consequence by regulatory authorities. This is noteworthy 
because from time to time, academic researchers revisit the toxicity of poligeenan in 
relation to food grade carrageenan. The most recent and vocal researcher to enter this 
arena is Dr. Joanne K. Tobacman, currently at the University of Illinois in Chicago. 
 
In Environmental Health Perspectives (EPH, 2001), a journal on environmental 
factors and human health, Dr. Tobacman  reviewed all scientific literature relating to 
carrageenan safety (Tobacman (2001).  The article reviewed 45 existing animal 
studies on poligeenan and carrageenan in relation to safety for food use. Critiques of 
the paper note how Dr. Tobacman ascribes results for poligeenan feeding studies to 
carrageenan and the disregard for how the method of administration to the animals 
can effect the results (Carthew, 2002; Cohen et al., 2002).   
 
A consequence of this confusion of two different materials is exemplified in a quote 
from the author‟s interview of Dr. Tobacman in December, 2003. 
 
„I guess that underlying this issue is the consideration about how much data are 
sufficient to make a judgement about carcinogenicity? Many animal studies 
demonstrating ulcerations and neoplasms from carrageenan (sic) exposure were 
completed decades ago. What evidence and how much evidence does it take to lead to 
changes in policy and behaviour? „(Tobacman, 2003, pers. Comm., 3 December). 
 
For Tobacman, rather than proving safety, the weight of evidence from past studies 
suggested that carrageenan in foods is a risk. As already discussed, shifts in regulatory 
policy in the 1950s required manufactures to produce „data‟ as evidence of safety. Her 
concern was also fuelled by a clause in the 1958 Amendment that related specifically 
to carcinogenicity – the so-called „Delaney clause‟.  The „Delaney clause‟ was 
introduced as an additional clause to the Food Additives Amendment in 1958 and 
mandated that:  
 
„…no additive shall be deemed safe if it is found to induce cancer when ingested by 
man or animal, or if it is found, after tests which are appropriate for the evaluation of 
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the safety of food additives, to induce cancer in man or animal…‟ (Quoted in Dean, 
1989, p. 6) 
 
Tobacman‟s opponents have continued to stress that she is mixing up the suspected 
carcinogenicity of poligeenan with the lack of any such toxicity of carrageenan 
(Cohen et al., 2002; Weiner et al., 2007). 
 
The application of the Delaney clause may also be evaluated in a contemporary policy 
context.  Merrill‟s (1997) review of regulatory policy demonstrates that the regulatory 
authorities did not anticipate, at the time the amendment was drafted, that the clause 
would be applied to a vast range of substances as subsequently occurred. 
 
„In 1958, neither advocates nor opponents of the policy, including FDA officials, 
believed it would have broad application, for only a handful of chemicals had then 
been shown to be animal carcinogens‟ (Merrill, 1997, p. 322) 
 
Knowledge of cancer-producing substances in the 1950s was largely confined to 
polycyclic aromatic hydrocarbons; at that time not even cigarette smoke was accepted 
as carcinogenic (Weisburger, 1994). Not surprisingly, the „zero risk‟ tolerance applied 
to „new‟ chemicals with potential carcinogenic effects  (new including regulated food 
additives not considered GRAS) has been extremely controversial (Merrill, 1997; 
Noah, 1999; Noah et al., 1998; Vogel, 2001; Weisburger, 1994).  Some argue that 
zero risk is necessary to protect the health of the public, others that carcinogens occur 
naturally in many foods and are of little risk (Ames et al., 1997, 1998). Noah (1999, p. 
34) suggests that the Delaney clause is used with less rigidity in food and drug law in 
the contemporary period because its wording preceded the development of more 
sensitive testing technologies and new medical knowledge about cancer. Where there 
is „reasonable certainty of no harm‟, the Delaney clause is no longer used. 
 
A second paper, Tobacman et al. (2001) in the journal Medical Hypotheses used an 
epidemiological technique known as a „time-trend‟ analysis to correlate the increased 
use of carrageenan in the twentieth century with the increased incidence of breast 
cancer. The authors wrote that „although time-trend correlations represent a weak 
form of evidence, when significant positive correlations are found, they can support 
further evaluation‟ (Tobacman et al., 2001a, p. 596). 
 
A further response to the Tobacman papers came from the European Commission 
Scientific Committee for Food.  A Commission report, prepared to review and 
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critique Tobacman‟s EPH and Medical Hypotheses papers, was critical of her findings 
in relation to the Medical Hypotheses article about which it concluded that it:  
 
…did not support the hypothesis that breast cancer may be causally related to intakes 
of carrageenan and other water-soluble polymers used as food additives. The 
Committee noted that such correlations might be found for any dietary component or 
chemical to which there has been increasing exposure during the twentieth century 
(Scientific Committee on Food, 2003a, p. 6).  
 
Furthermore, the Commission found nothing new in Tobacman‟s EPH review that 
had not already been considered by the Scientific Committee for Food in determining 
the safety, purity criteria and ADI for carrageenan.  
 
Although the report was critical of many of Tobacman‟s findings, there was one issue 
upon which the Committee felt further research should be undertaken – the possibility 
that „native‟ carrageenan could create significant amounts of poligeenan either by 
processing techniques or by acids during digestion. Like earlier controversies over 
baby formula the perception of risk in Europe was deemed serious enough to warrant 
a response. Thus regardless of the deficiencies of Tobacman‟s research, or the 
diagnostic use of poligeenan for imaging, a precautionary approach was adopted. The 
Committee suggested „if feasible, a molecular weight limit of not >5% below 50,000 
should be introduced into the specification to ensure that the presence of any (low 
molecular weight) carrageenan [in food] is kept to a minimum‟ (Scientific Committee 
on Food, 2003a, p. 6).  This specification is enforced today although no appropriate, 
validated analytical method is available to quantify the percentage of low molecular 
weight material in carrageenan. 
 
More recently Tobacman has published on bench top experiments on the interaction 
of carrageenan with various organ cells (Borthakur et al, 2007).  The continued focus 
of her research has been to implicate carrageenan as a carcinogen by association. 
However, what happens in vitro does not provide a sufficient evidence base for what 
occurs in vivo.  Even if a harmful relationship could be established in vitro, in vivo 
studies have demonstrated that ingested carrageenan does not pass the blood – gut 
barrier to interact with organ cells. Moreover, recent studies contradict cancer-
producing effects of carrageenan and indicate that k-carrageenan may, though the 
enhancement of immune systems, actually inhibit tumours (Yuan et al., 2006).  Work 
that seeks to establish a carrageenan/carcinogen link continues to be fuelled by 
suspicion. 
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Case IV  Semicarbazide - A new problem handled quickly 
Semicarbazide (SEM), a weak mutagen, was used for years in Europe as an indicator 
for the presence of  the banned veterinary antibiotic, Nitrofurazone (de la Calle et al., 
2005). The association between SEM and carrageenan came to attention through a 
circuitous route (summarized in Table 2).   
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Table 2. Public health concerns and semicarbazide  
Pre 1950s Azodicarbonamide (ADC) developed for use in plastics in Germany 
1993 Nitrofuran drugs used in animal husbandry banned in the European Union following 
findings of mutagenic potential – zero-tolerance rules applied 
2002 Semicarbazide (SEM), a known metabolite of nitrofurans used as marker for nitrofuran 
abuse – routine analysis begins with (more) sensitive methods  
2003 SEM found in foods of non-animal origin including tomato sauce, egg, high levels found 
in baby food   
2003 Denmark issues EC alert notification 2003/201 for „carrageen derived from see weed‟ 
from Canada, Chile, Indonesia and Tanzania in relation to SEM and nitrofurans 
2003 SEM linked to packaging and ADC used for PVC gaskets (extensive use in baby food) 
2003 European Food Safety Authority finds SEM has weak mutagenic activity, low risk to 
human health. Nevertheless concerns about high levels in baby food  
2004 Evidence of natural occurrence supports finding that SEM not a specific marker for 
nitrofuran abuse.  
2004 Seaweed Industry Association Philippines announces budget to study SEM in 
carrageenan. Industry begins to assess alternate methods of bleaching/halt to bleaching. 
June 2005 Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in 
Contact with Food concludes issue of carcinogenicity is not of concern for human health 
at the concentrations of SEM encountered in food.‟ 
2005 ADC banned from use in plastics 
 
The EC, EFSA and the World Health Organisation have declared that, based on levels 
reported in food, the health risk, if any, to consumers, including infants, appears to be 
very small (European Food Safety Authority, 2003; World Health Organization, 
2007). Nevertheless, at the time the issue came to light it created concerns that 
carrageenan could pose a risk to human health.  The carrageenan industry through its 
trade organization, Marinalg International, was required to perform tests for SEM on 
representative commercial carrageenan products and issue a response (Marinalg 
International, 2003).  
 
At the time this issue arose there was a zero tolerance limits for SEM in foods, and 
this combined with a subsequent discovery of SEM in baby food prompted what 
Hoeneick et al.(2006, p. 29) describes as „violent discussions‟. The discovery of SEM 
in carrageenan (Hoenicke et al., 2004) demonstrated to these researchers that it was 
not possible to differentiate between SEM resulting from Nitrofuran abuse; SEM 
occurring naturally or by bleaching processes involved in producing semi-refined 
carrageenan (PES).  Subsequently tests demonstrated that SEM had weak mutagenic 
activity and posed no risk to humans in the amounts likely to be consumed 
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(Abramsson-Zetterberg et al., 2005; AFC Panel, 2005; Hoenicke et al., 2006; 
Hoenicke et al., 2004). 
 
The SEM carrageenan issue is a reminder of the constitutive power of public health 
regulation in initiating suspicions of risk. Combined with concerns about carrageenan 
associated with dated understandings of ulcerations and cancers and potential harm to 
infants in liquid infant formula, the SEM example demonstrates that understanding 
risk associated with carrageenan also requires an understanding of the different 
regulatory settings and contexts in which „risks‟ emerge as public health issues. 
Despite all the concerns so far discussed, carrageenan is still regulated as safe. 
Discussion and conclusion 
 
After over fifty years of safe use of carrageenan in foods, some confusion and 
uncertainty in the public view still exists.  One reason for this is that scientific 
accounts of carrageenan risk rarely demonstrate the historical, regulatory and public 
health contexts. Carrageenan risks are routinely taken out of context (See for example 
Tobacman, 2001; Tobacman et al., 2001a; Tobacman et al., 2001b). 
 
A recent 90 day rat feeding study that was initiated to determine if a carrageenan near 
the lower molecular weight limit set by regulators (molecular weight of 257,000 
daltons with <5% below 50,000 daltons with a range of 1.9% – 12%, determined by 
four different methods) would cause any toxicological responses (Weiner et al., 
2006). The study concludes that carrageenan meeting regulatory purity criteria is safe 
for human consumption. On the basis of these findings the authors argue that the new 
molecular weight distribution specification for carrageenan in Europe is unnecessary. 
Studies of this type may help to clear up confusion from a scientific perspective, but 
they do not appear to resolve perceptions of safety in other contexts. 
 
An alternative framework for assessing and communicating risk is to review issues of 
safety in their broader use and health contexts. For example, it is rarely mentioned 
that carrageenan was intentionally degraded to make C16 for use in a specific 
pharmaceutical product for peptic ulcer that is no longer on the market.  The only use 
for this product today is industrial in nature (X-ray imaging diagnostics).  However, 
renaming C16 poligeenan and the product for food use carrageenan may not be 
sufficient to allay public concerns.  An extensive education program placing these 
different substances in a broader public health context may help. Without context a 
consumer could easily assume equivalence between carrageenan and poligeenan. 
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There is also the increased recognition of the potential value of carrageenan for 
antiviral, hypocholesterolaemic and hypoglycemic properties (Smit, 2004).  If current 
rounds of research prove successful, carrageenan will play an important part in sexual 
health applications, such as microbicides for HIV/AIDs prevention and use reduce the 
risk of cervical cancers by inhibiting the Human Papiloma Virus (Buck et al., 2006; 
Fernandez-Romero et al., 2007; Population Council, 2006). This diversity of possible 
new uses for carrageenan across different regulatory settings provides a complex 
context for assessing health risks and benefits, but the positive nature of these 
applications will help the public and regulators to understand the potential health 
effects of different products.  
 
This paper offers some insight into how various concerns within public health have 
influenced the risk regulatory process.  At present regulation has provided support for 
the safe use of carrageenan in food.  However, there is also the paradox that the more 
safety is proven, the more controversial that proof becomes.  
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